An in-vitro and in Silico Anticancer Study of FDA Approved Antidiabetic Drugs Glimepiride and Empagliflozin
Abstract
Drug repurposing is the way to find the role of the drug for new disease. Mostly the drug already passes human trails and approved by FDA. Many studies confirmed the role of many drugs in the treatment of more than one disease. Present research was conducted to evaluate the anticancer potential of FDA approved antidiabetic drugs Glimepiride and Empagliflozin. Glimepiride binds to ATP-sensitive potassium channel receptors and reduces the potassium conductance and Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. As many anti-diabetic drugs like meantime proved to be good anticancer drug so these two drugs were selected for the present study as their pharmacodynamics and pharmacokinetics studies are already reported and both showed no side-effect in human. The purpose of this study was to repurpose the Glimepiride and Empagliflozin as anticancer agents. In-vitro anticancer study was performed on two human cancer cell-lines MCF-7 and A549. To confirm the anticancer potential, the effect of these drugs on selected apoptotic proteins was studied in-silico. Both Glimepiride and Empagliflozin have significant anticancer activity on both the cell-lines but Empagliflozin seems to have better activity in-vitro. In-silico results indicated that both the drugs have significantly high activity towards apoptotic proteins. Although both the drug showed promising results in in-vitro and in-silico studies but the further studies like in-vivo studies are also required to…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.